Scientific Program
Home > Program > Scientific Program
  • September 7 (THU)
  • September 8 (FRI)

Sep. 7 (Thu)

ASCO/KSMO Joint Symposium 1 (JS01)

Targeting rare genomic aberrations in precision oncology
Date & Time September 7 (Thu), 08:40-10:10 Venue Room A
Chairs
  • Everett E. Vokes (ASCO Past President, University of Chicago Medicine and Biological Sciences, USA)
  • Joong Bae Ahn (Chair, Board of Directors, KSMO, Yonsei Cancer Center, Republic of Korea)
Session Details
  1. 1. Targeting NTRK fusion-positive cancers
    Lori J. Wirth (Massachusetts General Hospital, USA)
  2. 2. Clinical implication of BRAF aberrations in solid tumor
    Miso Kim (Seoul National University Hospital, Republic of Korea)
  3. 3.Ancestry-specific differences in TMB
    Amin Nassar (Yale New Haven Hospital, USA)
  4. 4.RAS/RAF aberrations in refractory cancer: What is next?
    Hee Kyung Kim (Chungbuk National University Hospital, Republic of Korea)

Satellite Symposium 1 (SL01)

Date & Time September 7 (Thu), 08:40-09:20 Venue Room B
Chair
  • Young Joo Min (Ulsan University Hospital, Republic of Korea)
Session Details
  1. Pembrolizumab and chemotherapy combinations, the global SOC in the 1st line treatment for NSCLC, HNSCC, and esophageal cancer
    Ji-Hyun Park (Konkuk University Medical Center, Republic of Korea)

Satellite Symposium 2 (SL02)

New era of 1st-line treatment for GC/GEJ/EAC with Nivolumab
Date & Time September 7 (Thu), 09:30-10:10 Venue Room B
Chair
  • Min-hee Ryu (Asan Medical Center, Republic of Korea)
Session Details
  1. 1. Real-World Practice of PD-L1 Testing for Nivolumab Plus Chemotherapy in Gastroesophageal Adenocarcinoma
    Hye Seung Lee (Seoul National University Hospital, Republic of Korea)
  2. 2. New Era of 1L Treatment for HER2 negative GC / GEJC / EAC with Nivolumab
    Min Kyu Jung (Yonsei Cancer Center, Republic of Korea)

Scientific Symposium 1 (SS01)

T cells need our help to fight cancer, beyond PD-1/PD-L1 inhibitors
The use of T cells in cancer immunotherapy has become a potent weapon in the fight against cancer. While Immune checkpoint inhibitors like PD-1/PD-L1 inhibitors
have revolutionized cancer treatment, primary and acquired resistance continue to pose significant challenges. To overcome these limitations, Innovative forms of
immunotherapy, such as adoptive T cell transfer and T cell redirection therapy, are now being researched actively. During this session, we will discuss these exciting
advances in cancer immunotherapy and their potential to enhance treatment outcomes.
Date & Time September 7 (Thu), 08:40-10:10 Venue Room C
Chairs
  • Prasad S. Adusumilli (Memorial Sloan Kettering Cancer Center, USA)
  • Dae Ho Lee (Asan Medical Center, Republic of Korea)
Session Details
  1. 1. Tumor-infiltrating lymphocyte (TIL) therapy, around the corner?
    Omid Hamid (The Angeles Clinic and Research Institute, USA)
  2. 2. HPK1 is a novel target for immune checkpoint inhibition
    Eui-Cheol Shin (KAIST Graduate School of Medical Science and Engineering, Republic of Kroea)
  3. 3. Enhancing T-cell effector profile in adoptive T cell therapy
    Chungyong Han (National Cancer Center, Republic of Korea)
  4. 4. CAR T cells for solid tumors; Advances and barriers
    Prasad S. Adusumilli (Memorial Sloan Kettering Cancer Center, USA)

Scientific Symposium 2 (SS02)

The next step in the treatment of GU cancers
This genitourinary cancer session deals with "next step" therapy. It consists of the direction of clinical trials and future landscape of clinical practice of new drugs,
which are currently being introduced in the treatment of genitourinary cancer, and how to make the best treatment choice in areas where there is not yet full consensus.
First, we will learn and discuss BiTE and CAR T in prostate cancer and ADC in urothelial carcinoma, and next about choosing initial treatments in metastatic hormone-sensitive prostate cancer and advanced renal cell carcinoma.
Date & Time September 7 (Thu), 08:40-10:10 Venue Room D
Chairs
  • Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, USA)
  • Hyo Jin Lee (Chungnam National University Hospital, Republic of Korea)
Session Details
  1. 1. Bi-specific T cell engager and CAR T in castration resistant prostate cancer: Hope or hype?
    Mike Groaning (Amgen, USA)
  2. 2. Antibody-drug conjugate in urothelial carcinoma: Current status and future perspectives
    Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, USA)
  3. 3. Combination treatment in metastatic castration sensitive prostate cancer: What to combine and how to sequence?
    Woo Kyun Bae (Chonnam National University Medical School and Hwasun Hospital, Republic of Korea)
  4. 4. The First-Line Treatment of Metastatic Renal Cell Carcinoma
    Jae Lyun Lee (Asan Medical Center, Republic of Korea)

Plenary Lecture 1 (PL01)

Mechanisms of resistance to endocrine therapy in ER+ breast cancer
Professor Carlos L. Arteaga, M.D., is an internationally recognized expert in breast cancer in the areas of oncogenes and breast tumor initiation and progression, targeted
therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. He is the Director of the Simmons Comprehensive
Cancer Center and Associate Dean of Oncology Programs at the University of Texas Southwestern Medical Center and served as the President of AACR. This plenary
lecture will be on resistance to endocrine therapy in breast cancer, with Dr. Arteaga giving his insights in tumor biology and novel therapeutics.
Date & Time September 7 (Thu), 10:40-11:20 Venue Room A
Chair
  • Seock-Ah Im (Seoul National University Hospital, Republic of Korea)
Session Details
  1. Mechanisms of resistance to endocrine therapy in ER+ breast cancer
    Carlos L. Arteaga (UT Southwestern Simmons Comprehensive Cancer Center, USA)

Luncheon Symposium 1 (LS01)

Date & Time September 7 (Thu), 11:30-12:10 Venue Room A
Chair
  • Sang-we Kim (Asan Medical Center, Republic of Korea)
Session Details
  1. Latest advances in small cell lung cancer treatment
    Hyun Ae Jung (Samsung Medical Center, Republic of Korea)

Luncheon Symposium 2 (LS02)

Date & Time September 7 (Thu), 11:30-12:10 Venue Room C
Chair
  • Kyung Hae Jung (Asan Medical Center, Republic of Korea)
Session Details
  1. Evolution and future of ribociclib in HR+HER2- mBC treatment
    Ji Yeon Kim (Samsung Medical Center, Republic of Korea)

Luncheon Symposium 3 (LS03)

Date & Time September 7 (Thu), 11:30-12:10 Venue Room E
Chair
  • Joo Hyuk Sohn (Yonsei University College of Medicine, Republic of Korea)
Session Details
  1. Change HER Destiny: Implementing ENHERTU in Practice and Practical Considerations
    Jae Ho JEONG (Asan Medical Center, Republic of Korea)

Scientific Symposium 3 (SS03)

Treatment for NSCLC: The earlier, the better?
There have been significant advances in adjuvant and neoadjuvant systemic chemotherapy for lung cancer, incorporating targeted agents and immunotherapy. These
clinical achievements are regarded as a significant opportunity to advance a cure for lung cancer. However, despite the progress, there are still limits in translating
clinical trial results into clinical practice. Further deliberation is needed to define more powerful predictive biomarkers before treatment or to develop subsequent
treatment strategies when expected responses are not achieved. In this session, we will discuss various clinical scenarios that arise when applying clinical research
results to real-world practice.
Date & Time September 7 (Thu), 12:30-14:00 Venue Room A
Chairs
  • Benjamin Besse (Gustave Roussy, France)
  • Sang-We Kim (Asan Medical Center, Republic of Korea)
Session Details
  1. 1. Neoadjuvant immunotherapy in NSCLC
    Mark Awad (Dana-Farber Cancer Institute, USA)
  2. 2. Adjuvant immunotherapy in NSCLC
    Benjamin Besse (Gustave Roussy, France)
  3. 3. Beyond treatment in recurred patients treated with upfront immunotherapy
    Hee Kyung Ahn (Gachon University Gil Medical Center, Republic of Korea)
  4. 4. Adjuvant EGFR TKI therapy, sooner is better than later, but not always!
    Dae Ho Lee (Asan Medical Center, Republic of Kroea)

Satellite Symposium 3 (SL03)

Date & Time September 7 (Thu), 12:30-13:10 Venue Room B
Chair
  • Keun Seok Lee (National Cancer Center, Republic of Korea)
Session Details
  1. Optimizing efficacy, safety and QOL balance of CDK 4/6 inhibitors in treating HR+/HER2- breast cancer patients
    Jieun LEE (The Catholic University of Korea Seoul St. Mary's Hospital, Republic of Korea)

Satellite Symposium 4 (SL04)

Date & Time September 7 (Thu), 13:20-14:00 Venue Room B
Chair
  • Jae Lyun Lee (Asan Medical Center, Republic of Korea)
Session Details
  1. The first ADC in la/mUC treatment, Enfortumab Vedotin landed in Korea
    In-Ho Kim (The Catholic University of Korea Seoul St. Mary's Hospital, Republic of Korea)

KSP/KSMO Joint Symposium (JS02)

Location matters: How spatial data is driving precision medicine
Date & Time September 7 (Thu), 12:30-14:00 Venue Room C
Chairs
  • Alexander Swarbrick (Garvan Institute of Medical Research, UNSW Sydney, Australia)
  • Yoon La CHOI (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. Spatial Transcriptomics in Oncology: Unveiling the Landscape of Tumor Heterogeneity
    Alexander Swarbrick (Garvan Institute of Medical Research, UNSW Sydney, Australia)
  2. 2. Current and future perspective of spatial transcriptome
    Jungmin Choi (Korea University College of Medicine, Republic of Korea)
  3. 3. The spatial context of tumor microenvironment
    Minsun Jung (Yonsei University College of Medicine, Republic of Korea)
  4. 4. Spatial tech to the clinic, how close are we? – A 10 years Singapore Odyssey to share
    Joe Yeong (Singapore General Hospital, Singapore)

KCSG/KSMO Joint Symposium (JS03)

The near future of precision medicine - One more step
Date & Time September 7 (Thu), 12:30-14:00 Venue Room D
Chairs
  • Dong-Wan Kim (Seoul National University Hospital, Republic of Korea)
  • Yeul Hong Kim (Yuhan Corporation, Republic of Korea)
Session Details
  1. 1. Spatial transcriptome analysis for cancer biology
    Woong-Yang Park (Samsung Medical Center, Republic of Korea)
  2. 2. The next horizon of precision oncology trials: Review of global research trends
    Yeon Hee Park (Samsung Medical Center, Republic of Korea)
  3. 3. Updates from the targeted agent and profiling utilization registry (TAPUR) study
    Richard L. Schilsky (The University of Chicago, USA)
  4. 4. Designing future clinical trials built on the basis of the KOSMOS II study
    Jee Hyun Kim (Seoul National University Bundang Hospital, Republic of Korea)

Scientific Symposium 4 (SS04)

Advance of perioperative chemotherapy in resectable or potentially resectable GI cancer
A deeper understanding of the molecular biology of cancer along with the introduction and application of new anticancer drugs have improved the efficacy of anticancer
therapy in metastatic digestive tract cancer. Recently, clinical trials on applying such effective chemotherapy even in cases where resection is possible have been actively
conducted, showing good results. In this session, we will discuss the peri-operative chemotherapy for resectable gastrointestinal cancer.
Date & Time September 7 (Thu), 14:10-15:40 Venue Room A
Chairs
  • Thierry CONROY (University of Lorraine, France)
  • Jong Gwang Kim (Kyungpook National University Chilgok Hospital, Republic of Korea)
Session Details
  1. 1. Application of perioperative chemotherapy for localized gastric cancer or gastroesophageal junction adenocarcinoma in Asian patients
    Sun Young Rha (Yonsei Cancer Center, Republic of Korea)
  2. 2. Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer
    Jin-Young Jang (Seoul National University Hospital, Republic of Korea)
  3. 3. Total neoadjuvant treatment in locally advanced rectal cancer
    Thierry Conroy (University of Lorraine, France)
  4. 4. Approach for resectable GI cancer with MSI-H
    Myriam Chalabi (Netherlands Cancer Institute, Netherlands)

Collaborative Symposium

Antibody-drug conjugates: Rise of new therapeutic strategies
Date & Time September 7 (Thu), 14:10-14:50 Venue Room B
Chair
  • Solange Peters (Lausanne University Hospital, Switzerland)
Session Details
  1. 1. Current and future perspectives on ADC strategies
    Solange Peters (Lausanne University Hospital, Switzerland)
  2. 2. Directing therapies to integrins in solid tumors
    Hyun Cheol Chung (Yonsei Cancer Center, Republic of Korea)

KOSRO/KSMO Joint Symposium (JS04)

Advances in non-operative, organ-preserving strategy
Date & Time September 7 (Thu), 14:10-15:40 Venue Room C
Chairs
  • Tomoya Yokota (Shizuoka Cancer Center, Japan)
  • Eui Kyu Chie (Seoul National University Hospital, Republic of Korea)
Session Details
  1. 1. Advances in non-operative, organ-preserving strategy
    William A. Hall (Medical College of Wisconsin, USA)
  2. 2. Multi-modality therapy to achieve intact-bladder survival
    Se Hoon Park (Samsung Medical Center, Republic of Korea)
  3. 3. Multidisciplinary less invasive approach for head and neck cancer
    Tomoya Yokota (Shizuoka Cancer Center, Japan)
  4. 4. Implication of immune cell (lymphocyte) dynamics during and after chemoradiotherapy in lung cancer patients undergoing maintenance immunotherapy
    Kyung Hwan Kim (Yonsei University College of Medicine, Republic of Korea)

Scientific Symposium 5 (SS05)

Advances in genomics technology and its clinical adaptation
The goal of this session is to showcase the latest advances in genomics technology and their clinical applications, fostering a deeper understanding of their potential in
shaping the future of personalized medicine. Our expert speakers will discuss the innovative EPIC-seq technique for inferring epigenetic expression from cell-free DNA
analysis, the integration of cell-free RNA in cancer studies, the use of whole-genome sequencing in clinical cancer diagnosis, and a data-centric approach that leverages
genomic and transcriptomic data to accelerate cancer drug discovery. Join us to explore the transformative potential of precision medicine in cancer.
Date & Time September 7 (Thu), 14:10-15:40 Venue Room D
Chairs
  • Maximilian Diehn (Stanford University, USA)
  • Duhee Bang (Yonsei University (Department of Chemistry), Republic of Korea)
Session Details
  1. 1. Circulating tumor DNA analysis for detection and molecular characterization of cancers
    Maximilian Diehn (Stanford University, USA)
  2. 2. Whole-genome sequencing for clinical diagnosis of cancer
    Young Seok Ju (Graduate School of Medical Science and Engineering, KAIST / Genome Insight Inc., Republic of Korea)
  3. 3. Single-cell RNA sequencing in analyzing molecular and cellular dynamics in lung cancer
    Hae-Ock Lee (The Catholic University of Korea, Republic of Korea)
  4. 4. Adopting a Data-Centric Approach to Fast Track Drug Target Identification - A Case Study
    Abhishek Jha (Elucidata Corporation, USA)

Oral Presentation 1 (OP01)

Date & Time September 7 (Thu), 14:40-15:40 Venue Room E
Chairs
  • Byoung-Yong Shim (The Catholic University of Korea St. Vincent's Hospital, Republic of Korea)
  • Tae-Yong Kim (Seoul National University Hospital, Republic of Korea)
Session Details
  1. 1. A Phase II Study of Tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
    Eun Joo KANG (Korea University Guro Hospital, Republic of Korea)
  2. 2. A phase II study of autologous natural killer cells with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma
    Woo Kyun BAE (Chonnam National University Medical School and Hwasun Hospital, Republic of Korea)
  3. 3. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
    Kyoo Hyun KIM (Yonsei University College of Medicine, Republic of Korea)
  4. 4. A phase I study of Nelmastobart (hSTC810), an anti-BTN1A1 antibody in advanced solid tumor patients
    Soohyeon LEE (Korea University Anam Hospital, Republic of Korea)
  1. 5. Combination immunotherapy targeting XBP1, CD138 and CS1 with cancer vaccine, checkpoint inhibitors, immune modulator, and epigenetic regulator to treat patients with myeloma or solid tumours: Clinical applications
    Jooeun BAE (Dana-Farber Cancer Institute, USA)

Plenary Lecture 2 (PL02)

Mechanism of action and inflammatory axis for air pollution induced non-small cell lung cancer
Professor Charles Swanton, FRCP BSc PhD, is a clinician scientist whose work is focused on understanding the challenges inherent in managing metastatic cancers
and their drug-resistant and incurable nature. He is the Chief Investigator of the TRACERx clinical study which deciphers lung cancer evolution, and his work has led
to insights in genomic diversity within cancers (intratumor heterogeneity) and molecular mechanisms driving cancer branched evolution.
Date & Time September 7 (Thu), 15:50-16:30 Venue Room A
Chair
  • Tae Won Kim (Asan Medical Center, Republic of Korea)
Session Details
  1. Mechanism of action and inflammatory axis for air pollution induced non-small cell lung cancer
    Charles Swanton (Francis Crick Institute, UK)

ESMO/KSMO Joint Symposium 1 (JS05)

Multiomics approach for precision medicine
Date & Time September 7 (Thu), 16:30-18:00 Venue Room A
Chairs
  • Andrés Cervantes (ESMO President, University of Valencia, Spain)
  • Kyung Hee Lee (KSMO President, Yeungnam University Medical Center, Republic of Korea)
Session Details
  1. 1. Biomarkers for Precision Oncology - Chances and Challenges
    Benedikt Westphalen (University of Munich, Germany)
  2. 2. Predictive factors for immunotherapy
    Rodrigo Dienstmann (Vall d'Hebron Institute of Oncology (VHIO), Spain)
  3. 3. Multiomics biomarker and immunotherapy: Yet to come
    Se-Hoon Lee (Samsung Medical Center, Republic of Korea)
  4. 4. Multiomics approach in EBV related solid cancer
    Jangho Cho (The Catholic University of Korea Incheon St. Mary's Hospital, Republic of Korea)

Satellite Symposium 5 (SL05)

Date & Time September 7 (Thu), 16:30-17:10 Venue Room B
Chair
  • Jong Gwang Kim (Kyungpook National University Chilgok Hospital, Republic of Korea)
Session Details
  1. Recent update in study for pattern, efficacy and safety of use of Bevacizumab or Cetuximab in patients with metastatic colorecatal cancer when added to FOLFIRI treatment
    Seung Hoon Beom (Yonsei Cancer Center, Republic of Korea)

Satellite Symposium 6 (SL06)

A new perspectives & future paradigm shift of treatment for advanced gastric cancer
Date & Time September 7 (Thu), 17:20-18:00 Venue Room B
Chair
  • Dae Young Zang (Hallym University Sacred Heart Hospital, Republic of Korea)
Session Details
  1. 1. How do we treat Advanced Gastric Cancer: biomarkers discovery and future systemic therapies?
    Jin-Soo Kim (Seoul National University BORAMAE Medical Center, Republic of Korea)
  2. 2. 2023 PRODIGY update: Role of Neoadjuvant with DOS regimen in locally advanced gastric cancer
    Hyung-Don Kim (Asan Medical Center, Republic of Korea)

Scientific Symposium 6 (SS06)

Artificial intelligence-empowered precision medicine in oncology: Cancer diagnosis, biomarker development, and drug discovery
Artificial intelligence (AI) technology has brought great changes in cancer diagnosis and treatment. A major example of using AI in the diagnostic field includes predicting
future cancer risk of individuals from normal mammography images before actual cancer development. By combining analysis of single cell sequencing technology and
pathology images, it is possible to analyze what genomic/transcriptomic features each cell has. In the therapeutic area, AI can predict the treatment response of novel
anti-cancer agents by analyzing the interaction between cancer cells and the microenvironment on a pathology slide. In addition, predicting and realizing the 3D structure
of proteins has led to great innovation in developing new drugs. In this session, experts in this field will share status updates on implementing AI in precision oncology
and share their perspectives.
Date & Time September 7 (Thu), 16:30-18:00
 Venue Room C
Chairs
  • Jeanne Shen (Stanford University, USA)
  • Chaok Seok (Seoul National University, Republic of Korea)
Session Details
  1. 1. Machine Learning for Personalized Cancer Screening
    Adam Yala (UC Berkeley and UCSF, USA)
  2. 2. Development and clinical application of histopathology-based deep learning models for precision oncology
    Jeanne Shen (Stanford University, USA)
  3. 3. AI-powered analysis of spatial transcriptomics for drug development and biomarker discovery
    Kwon Joong Na (Seoul National University Hospital, Republic of Korea)
  4. 4. Searching chemical and protein spaces using deep neural networks for drug discovery
    Chaok Seok (Seoul National University, Republic of Korea)

Scientific Symposium 7 (SS07)

The blueprint for next-generation therapeutics
In this session, we introduce next-generation anticancer therapeutics that are currently being actively developed through phase 1/2 clinical trials. In the first presentation,
we will introduce PROTAC inhibitors, which are gaining attention as the next generation of protein degraders in the field of hormonal therapy. In the second presentation,
the presenter will review the current status of developing therapeutics for TP53 mutations, which are frequently found in all types of cancer but have lacked effective
treatments so far. In the third presentation, we will hear about the development status of ADCs (Antibody-Drug Conjugates) from LegoChem Biosciences, a Korean ADC
development company. Lastly, we are interested in hearing about the prospects of developing new HRD targeting agents, including PARP1 selective inhibitors.
Date & Time September 7 (Thu), 16:30-18:00
 Venue Room D
Chairs
  • Ecaterina Elena Dumbrava (The University of Texas, MD Anderson Cancer Center, USA)
  • Joo Hyuk Sohn (Yonsei University College of Medicine, Republic of Korea)
Session Details
  1. 1. Development of Anti-Cancer PROTAC Agents
    Xin Gao (Massachusetts General Hospital, USA)
  2. 2. Targeting TP53 mutations using novel strategies
    Ecaterina Elena Dumbrava (The University of Texas, MD Anderson Cancer Center, USA)
  3. 3. New direction for ISAC development in cancer therapeutics
    Jeong-Hyun Ryou (Boostimmune, Inc., Republic of Korea)
  4. 4. Novel HRD targeting agents
    Elisabetta Leo (AstraZeneca, UK)

Sep. 8 (Fri)

Satellite Symposium 7 (SL07)

 
Date & Time September 8 (Fri), 08:00-08:40 Venue Room A
Chair
  • JoungSoon JANG (Uijeongbu Eulji Medical Center, Eulji Univeristy, Republic of Korea)
Session Details
  1. State-of-the-art Neo/Adjuvant treatment in pancreatic cancer: Guidance for oncologist
    Chung Ryul Oh (Chung-Ang University Hospital, Republic of Korea)

Satellite Symposium 8 (SL08)

 
Date & Time September 8 (Fri), 08:00-08:40 Venue Room C
Chair
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary’s Hospital, Republic of Korea)
Session Details
  1. Navigating the role of Lenvatinib in hepatocellular carcinoma : An up-to-date data review and emerging treatment strategies
    Jaekyung Cheon (Asan Medical Center, Republic of Korea)

Satellite Symposium 9 (SL09)

Where are we from a perspective of patient centricity in terms of Flexcare?
 
Date & Time September 8 (Fri), 08:00-08:40 Venue Room D
Chair
  • Yeon Hee Park (Samsung Medical Center, Republic of Korea)
Session Details
  1. HER2+ Breast Cancer: Adjuvant Pertuzumab and Patient-Centric Care
    Elaine Lim (National Cancer Center Singapore, Singapore)

Satellite Symposium 10 (SL10)

 
Date & Time September 8 (Fri), 08:00-08:40 Venue Room E
Chair
  • Hei-Cheul Jeung (Gangnam Severance Cancer Hospital, Republic of Korea)
Session Details
  1. Treatment for metastatic colorectal cancer : Focused on FTD/TPI
    Kyung Hye Bang (Chung-Ang University Gwangmyeong Hospital, Republic of Korea)

Plenary Lecture 3 (PL03)

SCRUM-MONSTAR & CIRCULATE - Japan platform to accelerate precision oncology innovations; achievement and perspective
Dr. Takayuki Yoshino, M.D. PhD, is the Director for the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East
(NCCE) in Chiba, Japan. He has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer (CRC), where he focuses on various
investigational new agents and translational research.
He is leading a nationwide cancer genome screening project to profile cancer-related genomic alterations in advanced solid tumors (SCRUM). In addition, he is studying
the gut microbiome in advanced solid tumors by circulating tumor DNA target panel sequencing and sequencing of 16S rRNA from gut microbiome (MONSTAR).
Date & Time September 8 (Fri), 09:00-09:40 Venue Room A
Chair
  • Taeyou Kim (Seoul National University Hospital, Republic of Korea)
Session Details
  1. SCRUM-MONSTAR & CIRCULATE - Japan platform to accelerate precision oncology innovations; achievement and perspective
    Takayuki Yoshino (National Cancer Center Hospital East, Japan)

ASCO/KSMO Joint Symposium 2 (JS06)

Recent updates in multimodality cancer treatment
Date & Time September 8 (Fri), 10:00-11:30 Venue Room A
Chairs
  • Lori J. Wirth (Massachusetts General Hospital, USA)
  • Ho Yeong Lim (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. Cellular Therapy Approaches and Preclinical Models for Gastric Cancer
    Sandra W. Ryeom (Columbia University Irving Medical Center, USA)
  2. 2. Recent advances in combined modality therapy of early-stage lung cancer
    Everett E. Vokes (University of Chicago, USA)
  3. 3. Multimodality treatment in HCC in the IO era
    Jung Yong Hong (Samsung Medical Center, Republic of Korea)
  4. 4. Multimodality treatment for brain metastasis of breast cancer in immunotherapy/antibody-drug conjugate era
    Min Hwan Kim (Yonsei University College of Medicine, Republic of Korea)

Satellite Symposium 11 (SL11)

Date & Time September 8 (Fri), 10:00-10:40 Venue Room B
Chair
  • Seock-Ah Im (Seoul National University Hospital, Republic of Korea)
Session Details
  1. Addressing unmet needs in the treatment of patients with metastatic triple-negative breast cancer
    Adam Brufsky (Comprehensive Breast Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh, USA)

Satellite Symposium 12 (SL12)

Date & Time September 8 (Fri), 10:50-11:30 Venue Room B
Chair
  • Ji-Youn Han (National Cancer Center, Republic of Korea)
Session Details
  1. Recent advances in targeting EGFR exon 20 mutations in non–small cell lung cancer: Mobocertinib
    Sun Min Lim (Yonsei University College of Medicine, Republic of Korea)

Scientific Symposium 8 (SS08)

Recent strategies in treatment advances for metastatic GI cancers
This session aims to explore the latest developments in treating metastatic gastrointestinal (GI) cancers. Experts will discuss exciting topics such as novel treatment
approaches for advanced gastric cancer, pancreatic cancer, and hepatocellular carcinoma, as well as tissue-agnostic targeted treatments. Attendees can expect to
learn about the most promising strategies and their potential benefits for patients with metastatic GI cancers, gaining insight into innovative treatment approaches
shaping the future of metastatic GI cancer care.
Date & Time September 8 (Fri), 10:00-11:30 Venue Room C
Chairs
  • Zev A. Wainberg (UCLA, USA)
  • Joon Oh Park (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. Advances in targeted therapies for AGC, beyond HER2 for gastric cancer
    Kohei Shitara (National Cancer Center Hospital East, Japan)
  2. 2. Novel approaches in treatments for advanced pancreatic cancer beyond chemotherapy
    Wungki Park (Memorial Sloan Kettering Cancer Center, USA)
  3. 3. Later-line treatment strategies for advanced HCC in "immunotherapy as 1st line" era
    Arndt Vogel (Hannover Medical School, Germany)
  4. 4. Tissue agnostic targeted treatment approaches for metastatic GI cancers
    Zev A. Wainberg (UCLA, USA)

Education Session 1 (ES01)

Basics of precision medicine for medical oncologists: What else should we know beyond NGS?
Undoubtedly, precision medicine has unleashed a totally new era of medical oncology conferring an obvious therapeutic benefit for our patients. Although we as
medical oncologists are becoming more familiar with NGS in our daily practice, it’s time to expand our comprehension of precision medicine beyond NGS. Accordingly,
this session will review, discuss, and offer insight on timely issues of precision medicine other than NGS. After summarizing the current status of cancer genomics, the
concept and application of proteomics and liquid biopsy will be introduced. Interestingly, the ways that AI and precision medicine are converging will also be shared.
Date & Time September 8 (Fri), 10:00-11:20 Venue Room E
Chairs
  • Sook Ryun Park (Asan Medical Center, Republic of Korea)
  • Tae Min Kim (College of Medicine, The Catholic University of Korea, Republic of Korea)
Session Details
  1. 1. Basics of precision medicine for medical oncologists: What else should we know beyond NGS?
    In Hae Park (Korea University Guro Hospital, Republic of Korea)
  2. 2. Single RNA sequencing and proteomics: How can we implement them in our research and practice?
    Han Sang Kim (Severance Hospital, Republic of Korea)
  3. 3. The role of AI in the era of precision medicine: When AI meets cancer genomics
    Chan-Young Ock (Lunit Inc., Republic of Korea)
  4. 4. Liquid biopsy in our clinics: Can it be another breakthrough in genomics-driven oncology
    Sun-Young Kong (National Cancer Center, Republic of Korea)

Luncheon Symposium 4 (LS04)

Date & Time September 8 (Fri), 11:40-12:20 Venue Room A
Chair
  • Seong-Hoon SHIN (Kosin University Gospel Hospital, Republic of Korea)
Session Details
  1. More TOMORROWs for her: Pembrolizumab, the cutting edge in women’s cancer
    Soo jung Lee (Kyungpook National University Chillgok Hospital, Republic of Korea)

Luncheon Symposium 5 (LS05)

Date & Time September 8 (Fri), 11:40-12:20 Venue Room C
Chair
  • Kyong Hwa Park (Korea University Anam Hospital, Repubic of Korea)
Session Details
  1. Long-term outcome of abemaciclib in HR+, HER2 - high-risk early breast cancer
    In Hae Park (Korea University Guro Hospital, Republic of Korea)

Luncheon Symposium 6 (LS06)

Date & Time September 8 (Fri), 11:40-12:20 Venue Room D
Chair
  • Ki Hyeong LEE (Chungbuk National University Hospital, Republic of Korea)
Session Details
  1. Lazertinib: Redefining the treatment journey in EGFR mutant NSCLC - From 1st line
    Byoung Chul CHO (Severance Hospital, Republic of Korea)

Scientific Symposium 9 (SS09)

Recent advances in breast cancer treatment
This scientific symposium will cover recent advances in breast cancer treatment, including the development of therapeutic agents and their successful application
in clinical settings. The development of CDK 4/6 inhibitors has completely changed the treatment paradigm in hormone receptor-positive breast cancer, and the
most promising drug currently receiving attention is oral SERD. Immunotherapy has become the standard of care for triple-negative breast cancer. Novel treatment
strategies beyond immunotherapy will be discussed. The discussion will also cover the current and future development of antibody-drug conjugates, such as T-DXd
and Sacituzumab govitecan, and the potential need to redefine breast cancer subtypes based on their response to these agents.
Date & Time September 8 (Fri), 12:40-14:10 Venue Room A
Chairs
  • Soo Chin Lee (Cancer Science Institute of Singapore, National University of Singapore (NUS), Singapore)
  • Young Hyuck Im (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. The role of oral SERD in ER+ breast cancer
    Soo Chin Lee (Cancer Science Institute of Singapore, National University of Singapore (NUS), Singapore)
  2. 2. State of the art and future directions of antibody-drug conjugates (ADCs) in breast cancer
    Barbara Pistilli (Gustave Roussy, France)
  3. 3. Novel treatments for metastatic triple-negative breast cancer: Beyond immunotherapy
    Andrei Goga (University of California San Francisco, USA)
  4. 4. Should breast cancer subtype be re-established?
    Kyong Hwa Park (Korea University Anam Hospital, Republic of Korea)

Satellite Symposium 13 (SL13)

Date & Time September 8 (Fri), 12:40-13:20 Venue Room B
Chair
  • Joon Oh Park (Samsung Medical Center, Republic of Korea)
Session Details
  1. Optimizing Treatment for Patients with Metastatic Pancreatic Cancer
    Jeesun Yoon (Seoul National University Hospital, Republic of Korea)

JSMO/KSMO Joint Symposium (JS07)

Emerging immuno-oncology strategy in solid tumors
Date & Time September 8 (Fri), 12:40-14:10 Venue Room C
Chairs
  • Shigehisa Kitano (Cancer Institute Hospital of JFCR, Japan)
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary’s Hospital, Republic of Korea)
Session Details
  1. 1. Anti-cancer cell therapy in solid tumors
    Yasutoshi Kuboki (National Cancer Center Japan, Japan)
  2. 2. Combination of immune checkpoint inhibitors in solid tumors
    Shigehisa Kitano (The Cancer Institute Hospital of Japanese Foundation For Cancer Research (JFCR), Japan)
  3. 3. Combination of ICI and targeted agent in solid tumors
    Moon Ki Choi (National Cancer Center, Republic of Korea)
  4. 4. Combination of ICI and cytotoxic chemotherapy in solid tumors
    In-Ho Kim (The Catholic University of Korea Seoul St. Mary's Hospital, Republic of Korea)

Master Class (MC)

When common cancer meets NGS

Date & Time September 8 (Fri), 12:40-14:20 Venue Room D
Chairs
  • Jin Seok Ahn (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. KRAS mutation: How should we act on it?
    Sun Min Lim (Yonsei University College of Medicine, Republic of Korear)
  2. 2. MET-targeted therapies – About time we MET
    Tae Min Kim (Seoul National University Hospital, Republic of Korea)
  3. 3. New targeted therapies for EGFR exon 20 insertion
    Beung Chul Ahn (National Cancer Center, Republic of Korea)
  4. 4. RET fusion as a novel actionable target in NSCLC
    Min Hee Hong (Yonsei Cancer Center, Republic of Korea)

Education Session 2 (ES02)

Practical points in conducting clinical trials
With the development of anticancer drugs using various mechanisms, many kinds of clinical trials have been conducted in which numerous patients have been
registered. There can be significant hurdles to conducting clinical trials, including understanding tests and handling adverse events. In this session, we
would like to share professional experience and enhance knowledge on the practical points of clinical trials.
Date & Time September 8 (Fri), 12:40-14:10 Venue Room E
Chairs
  • Sung Yong Oh (Dong-A University Hospital, Republic of Korea)
  • Keon Uk Park (Keimyung University Dongsan Medical Center, Republic of Korea)
Session Details
  1. 1. Understanding pathology tests from immunohistochemistry to NGS
    Hyojin Kim (Seoul National University Bundang Hospital, Republic of Korea)
  2. 2. Prevention of chemotherapy-induced nausea and vomiting
    In Hee Lee (Kyungpook National University School of Medicine, Republic of Korea)
  3. 3. Management of adverse events associated with tyrosine kinase inhibitors
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Republic of Korea)
  4. 4. Diagnosis and management of immune-related adverse events
    Jae-Joon Kim (Pusan National University Yangsan Hospital, Republic of Korea)

Plenary Lecture 4 (PL04)

Breakthroughs in targeted therapy and immunotherapy for the treatment of advanced non-small cell lung cancer
Professor Roy S. Herbst, MD, PhD, is a highly respected clinician scientist who has championed novel therapies and research linking genetic abnormalities
of cancer cells for lung cancer treatment. He revolutionized the field by introducing diverse molecular targeted therapies and immune checkpoint inhibitors.
His work on "umbrella” trials has galvanized the field of targeted therapy and he led BATTLE-1, BATTLE-2 and Lung-MAP. In his lifetime of achieving scientific
contributions in thoracic cancer research, he has made significant advances for the benefit of patients with cancer.
Date & Time September 8 (Fri), 14:20-15:00 Venue Room A
Chair
  • Jin-Hyuk Choi (Ajou University Hospital, Republic of Korea)
Session Details
  1. Breakthroughs in targeted therapy and immunotherapy for the treatment of advanced non-small cell lung cancer
    Roy S. Herbst (Yale School of Medicine, USA)

KSR/KSMO Joint Symposium (JS08)

Integrating interventional techniques in the immunotherapy landscape: Novel insights from radiology and oncology
Date & Time September 8 (Fri), 15:00-16:00 Venue Room A
Chairs
  • Do-Youn Oh (Seoul National University Hospital, Republic of Korea)
  • Youngjoon Lee (The Catholic University of Korea Eunpyeong St. Mary's Hospital, Republic of Korea)
Session Details
  1. 1. Radioembolization for liver metastasis and cholangiocarcinoma: Hot air or hot stuff
    Hyo-Cheol Kim (Seoul National University Hospital, Republic of Korea)
  2. 2. Radiology perspective: Combining image-guided ablation for enhanced cancer treatment
    Hyun Pyo Hong (Kangbuk Samsung Hospital, Republic of Korea)
  3. 3. Immunotherapy in hepatocellular carcinoma
    Hong Jae Chon (CHA Bundang Medical Center, Republic of Korea)

Oral Presentation 2 (OP02)

Date & Time September 8 (Fri), 15:00-16:00 Venue Room B
Chairs
  • Sang Cheul Oh (Korea University Guro Hospital, Republic of Korea)
  • Keun-Wook LEE (Seoul National University Bundang Hospital, Republic of Korea)
Session Details
  1. 1. Safety and efficacy of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracycline and taxane in real-world clinical practice: data from post-marketing surveillance in Korea
    Yee Soo CHAE (Kyungpook National University Chilgok Hospital, Republic of Korea)
  2. 2. Luminal-to-basal subtype conversion is associated with TP53-GATA3 mutational status in patients with advanced breast cancer
    Won-Ji RYU (Yonsei University College of Medicine, Republic of Korea)
  3. 3. Phase II trial of lazertinib in EGFR-mutated metastatic non-small cell lung cancer patients with brain metastases after failure to prior EGFR tyrosine kinase inhibitor (KCSG LU 20-15)
    Min Hee HONG (Yonsei Cancer Center, Republic of Korea)
  4. 4. Analysis of ctDNA in EGFR/HER2 co-expressing advanced gastric cancer treated with second-line varlitinib and paclitaxel chemotherapy (K-MASTER-13)
    Dong-Hoe KOO (Kangbuk Samsung Hospital, Republic of Korea)
  5. 5. Prospective trial for clinical utility of cancer whole-genome sequencing in adult solid tumors
    Minsuk KWON (Ajou University Hospital, Republic of Korea)
  6. 6. Plasma Proteome Profiling of 1,118 Pan-cancer Patients Define Molecular Characteristics and Biomarkers of Human Cancers
    Youchao JIA (Affiliated Hospital of Hebei University；Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, China)

Multi-Disciplinary Case Discussion (MDCD)

Multidisciplinary approach for patients with oligo-metastasis in the era of precision medicine
The role of the oncology multidisciplinary team has become a key component in the care management pathway, helping to ensure that increasingly complex treatment
strategies now available are appropriately selected and combined for each individual patient. In this session, we discuss management options for oligometastatic cancer,
including an overview of surgical concepts, the current literature on local ablative techniques including stereotactic ablative radiotherapy (SABR), and systemic therapy
as an adjunct to local treatment strategies.
Date & Time September 8 (Fri), 15:00-16:00 Venue Room C
Chairs
  • In Hae Park (Korea University Guro Hospital, Republic of Korea)
  • Sun Young Rha (Yonsei Cancer Center, Republic of Korea)
Session Details
  1. Part 1. Practical management in oligometastatic breast cancer?: When, Who, How
    Min Hwan Kim (Yonsei University College of Medicine, Republic of Korea)
    [Panel Discussion]
    Hyeong-Gon Moon (Seoul National University Hospital, Republic of Korea)
    Kyubo Kim (Ewha Womans University Mokdong Hospital, Republic of Korea)
    In Hae Park (Korea University Guro Hospital, Republic of Korea)
  2. Part 2. How to treat oligometastatic gastric cancer?
    Jin Won Kim (Seoul National University Bundang Hospital, Republic of Korea)
    [Panel Discussion]
    In-seob Lee (Asan Medical Center, Republic of Korea)
    Jeong Il Yu (Samsung Medical Center, Republic of Korea)
    Sun Young Rha (Yonsei Cancer Center, Republic of Korea)

Education Session 3 (ES03)

ABCs of novel therapeutics for solid cancers: What should we know?
The various challenges undertaken to improve survival rates in oncology are paying off. As new radiation therapy and various ADCs in the field of targeted therapy
are being developed, the expectations for new treatments are increasing. In addition, new research results are being reported in oncolytic viruses that have been
studied and developed for a long time. This education session will cover the latest insights on proton and carbon therapy, ADCs, and oncolytic virus therapy for
researchers entering the changing field of oncology and looking for advanced treatments in addition to those now existing.
Date & Time September 8 (Fri), 15:00-16:30 Venue Room D
Chairs
  • Han Jo Kim (Soonchunhyang University Hospital Cheonan, Republic of Korea)
  • Hye Jin Choi (Yonsei University College of Medicine, Republic of Korea)
Session Details
  1. 1. Proton therapy and carbon ion therapy for solid cancers
    Yang-Gun Suh (National Cancer Center, Republic of Korea)
  2. 2. Antibody-drug conjugate for targeted cancer treatment
    Kwang Suk Lim (Kangwon National University, Republic of Korea)
  3. 3. Oncolytic virus therapy for cancer
    Kimun Kwon (Inno.N, Republic of Korea)

FACO Session 1 (FACO01)

Recent updates in colorectal cancer treatment
Date & Time September 8 (Fri), 15:00-16:00 Venue Room E
Chairs
  • Jin Li (FACO Chairman, China)
  • Young Suk Park (Samsung Medical Center, Republic of Korea)
Session Details
  1. 1. Recent progress in neoadjuvant treatment for locally advanced rectal cancer
    Sun Young Kim (Asan Medical Center, Republic of Korea)
  2. 2. Does checkpoint inhibitor work in microstallite stable mCRC patients?
    Ying Yuan (The Second Affiliated Hospital Zhejiang University School of Medicine, China)
  3. 3. Beyond the scalpel: Advancing colorectal cancer management through ctDNA liquid biopsy
    Eiji Oki (Kyushu University, Japan)

ESMO/KSMO Joint Symposium 2 (JS09)

Immunooncology: Holistic perspectives for oncologists
Date & Time September 8 (Fri), 16:10-17:40 Venue Room A
Chairs
  • Hye Ryun KIM (Yonsei Cancer Center, Republic of Korea)
  • Kyung Hae Jung (Asan Medical Center, Republic of Korea)
Session Details
  1. 1. Molecular tissue imaging to predict response to immunotherapy
    Jo Van Ginderachter (Vrije Universiteit Brussel, Belgium)
  2. 2. Microbiota and nutrition to enhance immunotherapy treatment outcome
    Lisa Derosa (Institut Gustave Roussy, France)
  3. 3. Patient status and response to immunotherapy: From bed to benchside
    Hye Ryun Kim (Yonsei Cancer Center, Republic of Korea)
  4. 4. (Neo)adjuvant immunotherapy in triple negative breast cancer: Balance between efficacy and permanent toxicities
    Ji-Yeon Kim (Samsung Medical Center, Republic of Korea)

Satellite Symposium 14 (SL14)

Date & Time September 8 (Fri), 16:10-16:50 Venue Room B
Chair
  • Sun Young KIM (Asan Medical Center, Republic of Korea)
Session Details
  1. Digital solutions for precision medicine - Highly curated genomic analysis platform
    Cindy Shen HUANG (Roche Diagnostics, APAC Region, Taiwan)

Satellite Symposium 15 (SL15)

Date & Time September 8 (Fri), 17:00-17:40 Venue Room B
Chair
  • Se Hoon Park (Samsung Medical Center, Republic of Korea)
Session Details
  1. Real World data and treatment experience with Avelumab in patients with locally advanced or metastatic urothelial carcinoma; Focusing on first real world results from Korean Expanded Access Program
    Inkeun Park (Asan Medical Center, Republic of Korea)

KSSO/KSMO Joint Symposium (JS10)

Hereditary cancer - Diagnosis & proper management
Date & Time September 8 (Fri), 16:10-17:40 Venue Room C
Chairs
  • Jin Seok Ahn (Samsung Medical Center, Republic of Korea)
  • In-ja Park (Asan Medical Center, Republic of Korea)
Session Details
  1. 1. Testing criteria of hereditary cancer and clinical application
    Kyung-Hun Lee (Seoul National University Hospital, Republic of Korea)
  2. 2. How to prevent hereditary cancer other than surgery
    Ji Soo Park (Yonsei Cancer Center, Republic of Korea)
  3. 3. Risk reducing surgery in hereditary breast cancer
    Jai Min Ryu (Samsung Medical Center, Republic of Korea)
  4. 4. Risk reducing surgery in hereditary colon cancer
    Ji Won Park (Seoul National University Hospital, Republic of Korea)

FACO Session 2 (FACO02)

Proposals for new FACO clinical trials
Date & Time September 8 (Fri), 16:10-17:40 Venue Room E
Chairs
  • Masahiko Nishiyama (FACO CEO, Higashi Sapporo Hospital, Japan)
  • Dong-Wan Kim (Seoul National University Hospital, Republic of Korea)
Session Details
  1. 1. Clinical trials: from the viewpoint of lung cancer medical oncologist
    Sehhoon Park (Samsung Medical Center, Republic of Korea)
  2. 2. Clinical trials: From the viewpoint of a gynecologic oncologist
    Ning Li (National Cancer Center/Cancer Hospital (Institute) Chinese Academy of Medical Sciences & Peking Union Medical College, China)
  3. 3. International Collaboration in Gynecological Cancer Trials
    Keiichi Fujiwara (Saitama Medical University and International University of Health and Welfare, Japan)